BRAK
- Known as:
- BRAK
- Catalog number:
- CHM-239
- Product Quantity:
- 5µg
- Category:
- -
- Supplier:
- Prospecbio
- Gene target:
- BRAK
Related genes to: BRAK
- Gene:
- CXCL14 NIH gene
- Name:
- C-X-C motif chemokine ligand 14
- Previous symbol:
- SCYB14
- Synonyms:
- BRAK, NJAC, bolekine, Kec, MIP-2g, BMAC, KS1
- Chromosome:
- 5q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-30
- Date modifiied:
- 2016-10-05
Related products to: BRAK
Anserine Breast And Kidney Expressed Chemokine Elisa Kit (BRAK)Anserine anti - Breast And Kidney Expressed Chemokine Elisa Kit (BRAK)Anti-Human BRAKAnti-Human BRAKAnti-Human BRAKAnti-human BRAK, bt, Source: Polyclonal bt. Rabbit, PABAnti-human BRAK, bt, Source: Polyclonal bt. Rabbit, PABAnti-human BRAK, bt, Source: Polyclonal bt. Rabbit, PABAnti-human BRAK, Source: Polyclonal Goat, PABAnti-human BRAK, Source: Polyclonal Goat, PABAnti-human BRAK, Source: Polyclonal Goat, PABAnti_Human, pab BRAK Source RabbitBiotinylated Anti-Human BRAKBiotinylated Anti-Human BRAKBiotinylated Anti-Human BRAK Related articles to: BRAK
- To identify peripheral blood biomarker candidates for coronary artery disease (CAD) and to test whether bioinformatically prioritized genes replicate in an angiography-confirmed cohort, with emphasis on HIST1H2AE as an epigenetically relevant marker. - Source: PubMed
Publication date: 2026/04/15
Xu LiugangWang YajunJi HongyunShan YisiZhang JinhuYang LiDu WeiJiang JianyuChen JinCao Ruihong - Chen et al. demonstrate that NSCLC patients with COPD exhibit superior anti-PD-1 responses through a distinctive immunological mechanism. COPD-driven epithelial remodeling expands CXCL14+ basal-like tumor cells, which orchestrate CXCL9+ macrophage recruitment via CXCL14-CXCR4 signaling, amplifying cytotoxic T cell infiltration. This COPD-associated tumor-macrophage axis predicts pathological response and represents both a promising biomarker and potential therapeutic target for refining immunotherapy strategies. - Source: PubMed
Wang HaoweiJiang Tao - Ablative fractional carbon dioxide (AFCO) laser therapy is used for treating pathological scarring. However, mechanisms underlying reduction in hypertrophic scarring are poorly understood. - Source: PubMed
Publication date: 2026/04/10
Chen Yung-YiMahony ChristopherTurner JasonSmith Charlotte GAbdulsalam AbdulrazakAmirize EzekwePrince AmberleyHeagerty AdrianRoberts ClaudiaCroft AdamWilson YvonneMoiemen NaiemLord Janet M - Hyperuricemic nephropathy (HN) represents a major contributor to chronic kidney disease and is marked by progressive renal fibrosis accompanied by profound metabolic disturbances. Despite its clinical importance, the spatial coordination between metabolic remodeling and intercellular communication within the HN microenvironment remains poorly defined. - Source: PubMed
Publication date: 2026/04/06
Tu ChaoTao QianruLu YanChang HainingLuo KaiZhou Jun - Prostate cancer (PCa) is prototypically immunologically "cold", characterized by low tumor mutational burden, sparse CD8 T-cell infiltration, and resistance to immune checkpoint blockade. The tumor cell-intrinsic programs driving immune evasion in this context remain incompletely defined. - Source: PubMed
Publication date: 2026/03/18
Liu WeihaoLi GuopingLei YanLiu HuixiuWang BinhuiDeng WeimingHong YudeLong Xiangyang